Cardano retraces – Profit-taking threat looms once again

ambcryptoPublished on 2026-03-02Last updated on 2026-03-02

Abstract

Cardano (ADA) has been range-bound between $0.246 and $0.305 for most of February, with recent gains pushing it back into the top 10 cryptocurrencies by market cap. However, the short-term trend remains uncertain. On-chain data shows rising mean coin ages since January, indicating network-wide accumulation, while dormant circulation has been low. The 30-day MVRV ratio is at -3.65%, suggesting recent buyers are at a slight loss. Historically, a move into positive MVRV territory has preceded sell-offs, as seen in early January. Traders should be cautious, as profit-taking pressure could lead to a downturn, despite the current signs of accumulation.

Cardano [ADA] has lacked a prevalent trend throughout February. It has traded between $0.246 and $0.305 for most of the past month. Brief price wicks above or below these local extremes were quickly reversed.

At the time of writing, ADA was trading at the midpoint between these key S/R levels. The trading volume picked up over the volatile weekend.

The gains made since the 25th of February have propelled Cardano back to the top 10 crypto assets by market capitalization, AMBCrypto reported.

Ousting Bitcoin Cash [BCH] from the top 10 was no small feat, but the short-term trend still lacked conviction. The $0.27 short liquidation levels pile-up was squeezed, as AMBCrypto hinted it might be a week ago.

Examination of the on-chain metrics shed further light on what Cardano traders and investors could expect next.

Profit-taking pressure is a threat

The 90-day and 365-day mean coin ages have been trending higher since January. They witnessed a steep drop in December. At the same time, the dormant circulation had also registered 2025’s biggest peak.

The dormant circulation spike in December highlighted a high quantity of ADA tokens moving on-chain, which had previously been dormant for a long time.

The fall in mean coin age showed that tokens of different ages were being moved, likely due to the duress the market faced back then.

Over the past two months, the rising mean coin ages reflected network-wide Cardano accumulation. The dormant circulation was also quiet, agreeing that on-chain coin movements were relatively muted.

At the same time, the short-term holders were nearing breakeven or realizing profits. The 30-day MVRV was at -3.65%, meaning that ADA buyers within the past 30 days were facing a 3.65% loss on average.

The last time this metric became positive, ADA prices made a double top at $0.426 in early January before trending lower. Meanwhile, 90-day MVRV values were deep in negative territory, signaling dejected holder sentiment.


Final Summary

  • Traders and investors would be thrilled to see the rising mean coin age metrics, but remember that the longer-term trend has been bearish since September 2025.
  • The 30-day MVRV was nearing positive values. The last time it happened in January, a strong sell-off followed.

Trending Cryptos

Related Reads

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbit38m ago

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbit38m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbit38m ago

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbit38m ago

Trading

Spot

Hot Articles

Discussions

Welcome to the HTX Community. Here, you can stay informed about the latest platform developments and gain access to professional market insights. Users' opinions on the price of ADA (ADA) are presented below.

活动图片